Boston Scientific accounts are for healthcare professionals only.
Overview
Treat kidney stones and benign prostatic hyperplasia (BPH)
Backed by extensive clinical evidence, Lumenis Pulse 120H Holmium Laser System with MOSES 2.0 Technology is proven to optimize energy delivery with versatility for stone and BPH procedures.
Learn more about versatility and get product specifications.
Reducing retropulsion in lithotripsy treatment of kidney stones
For the treatment of stone disease, holmium laser lithotripsy is designed to be an effective tool for ablation. However, during standard laser lithotripsy, high-energy pulses may reduce procedural control, causing unwanted retropulsion of stone fragments. With recent advances in pulse modulation technology, this migration can be better managed from the outset.
MOSES™ 2.0 Technology uses patent-protected dual-pulse modulation to greatly improve energy transmission. Backed by robust clinical evidence, MOSES™ has demonstrated nearly a 50% reduction in stone retropulsion,1 a 33% improvement in fragmentation efficiency,1 and a 20% reduction in procedure time compared to standard holmium pulse models.1
How it works
Versatile by design
MOSES 2.0 Technology delivers remarkable efficiency and versatility.
Browse product categories
Frequently Asked Questions
Using pulse modulation technology, MOSES™ has demonstrated 50% reduction in retropulsion compared to standard holmium laser pulses, potentially minimizing incidents of ureteral stone migration into the kidney and avoiding stone-chasing.1
Patent-protected pulse modulation technology like MOSES™ greatly improves energy transmission, demonstrating nearly 20% reduction in procedure time, 33% improvement in fragmentation efficiency, and 50% reduction in stone retropulsion compared to standard holmium pulse.1
In a bench study, using MOSES™ Technology for lithotripsy demonstrated less heat generation compared to standard holmium long pulse at some settings.2
Yes, the Lumenis Pulse 120H laser system with MOSES technology is a comprehensive, versatile platform, raising the standard and improving efficiency for both stones and BPH treatments in a value-based healthcare system.1,3
Physician-driven, patient-centered innovation
Whether you need more information about our benign prostatic hyperplasia or other urology products, access to education programs, or have a question about reimbursement, we can help.
References:
- Ibrahim A, Elhilali MM, Fahmy N, et al. Double-blinded prospective randomized clinical trial comparing regular and Moses modes of holmium laser lithotripsy. J Endourol. 2020 May;34(5):624–8.
- Winship B, Stevens Terry R, Boydston K, et al. Holmium:YAG laser pulse type affects irrigation temperatures in a benchtop ureteral model. J Endourol. 2019;33(11). doi:10.1089/end.2019.0496.
- Kavoussi NL, Nimmagadda N, Robles J, et al. MOSES technology for holmium laser enucleation of the prostate: A prospective double-blind randomized control trial. J Urol. 2021 Jul;206(1):104–8.
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.
Boston Scientific acquired the global surgical business of Lumenis Ltd. Some registered names of products manufactured and sold by Boston Scientific may contain the term “Lumenis.” Lumenis is a registered trademark of Lumenis Be.
All images are the property of Boston Scientific. All trademarks are the property of their respective owners.